Show simple item record

dc.contributor.authorFatimilehin, Abiola
dc.contributor.authorBewley, Michelle
dc.contributor.authorBowen Jones, Sarah
dc.contributor.authorChan, Clara
dc.contributor.authorCoote, Joanna H
dc.contributor.authorHarris, Catherine
dc.contributor.authorHarris, Maggie A
dc.contributor.authorPemberton, Laura S
dc.contributor.authorSalem, Ahmed
dc.contributor.authorSheikh, Hamid Y
dc.contributor.authorTurpin, Zoe
dc.contributor.authorWhitehurst, Philip
dc.contributor.authorWooder, Rachael
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorBayman, Neil A
dc.contributor.authorWoolf, David K
dc.date.accessioned2021-07-28T12:41:50Z
dc.date.available2021-07-28T12:41:50Z
dc.date.issued2021en
dc.identifier.citationFatimilehin A, Bewley M, Bowen Jones S, Chan C, Coote J, Harris C, et al. Real world outcomes in patients with lung oligometastases treated with SABR – a single-centre experience. Lung Cancer . 2021 Jun;156:S58–9.en
dc.identifier.urihttp://hdl.handle.net/10541/624221
dc.description.abstractIntroduction: Delivering Stereotactic Ablative Body Radiotherapy (SABR) to patients with extracranial oligometastatic disease has the potential to improve long-term disease control, survival and defer changes to systemic therapies [1]. We present the results from an audit of patients treated with SABR under the NHS Commissioning through Evaluation (CtE) scheme at The Christie Hospital, Manchester UK. Methods: The outcomes of patients who received SABR to lung lesions or thoracic nodes under CtE were analysed. Prescribed doses included 30-60Gy in 3-8 fractions to nodes and 54-60 Gy in 3-8 fractions to lung lesions. Patients were eligible if aged ≥18, had ≤3 metastatic lesions, WHO performance status of ≤2, onset of metastatic disease was ≥6 months from the primary tumour diagnosis and life expectancy estimated to be ≥6 months. The main outcomes evaluated included local control (assessed by local radiologists) and overall survival which were obtained from hospital records. Adverse events by CTCAE grade were recorded prospectively. Results: 52 patients treated between February 2016 and August 2019 were included. Median follow up was 28.5 months and median age was 72 (range 49-90 years). 51.9% were female and 75% had a performance status of 0-1. The most common primary was colorectal (n=23; (44.2%)). 5 patients received SABR to thoracic nodes, and 8 patients had >1 lesion treated. The median BED10 dose was 121 Gy. Local control was 96% at 1 year and 84.6% at 2 years. Overall survival was 94.2% at 1 year and 89.7% at 2 years. One patient had a toxicity graded ≥3, which was fatigue. Conclusion: The findings demonstrate high levels of local control and overall survival in these patients, with low rates of toxicity. Our findings are comparable to the overall national results, and SABR to oligometastatic lesions has now been commissioned.en
dc.language.isoenen
dc.titleReal world outcomes in patients with lung oligometastases treated with SABR - a single-centre experienceen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester,en
dc.identifier.journalLung Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record